Oramed Pharmaceuticals (ORMP) Income from Non-Controlling Interests (2012 - 2025)
Oramed Pharmaceuticals (ORMP) posted Income from Non-Controlling Interests of -$6000.0 for Q3 2025, up 78.57% on a QoQ basis from -$28000.0 in Q2 2025, and up 73.91% year-over-year from -$3450.0 in Q3 2024.
Oramed Pharmaceuticals (ORMP) Income from Non-Controlling Interests (2012 - 2025) Analysis & Trends
Oramed Pharmaceuticals' Income from Non-Controlling Interests history runs 12 years deep, the most recent figure standing at -$6000.0 for Q3 2025.
- Quarterly Income from Non-Controlling Interests rose 73.91% year-over-year to -$6000.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$44000.0 (down 2.33% YoY) and the FY2025 annual result came in at -$34000.0, up 20.93% from the prior year.
- Income from Non-Controlling Interests was -$6000.0 for Q3 2025 at Oramed Pharmaceuticals, up from -$28000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $834000.0 in Q4 2023 and bottomed at -$751000.0 in Q3 2021.
- A 5-year average of -$132533.3 and a median of -$62000.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2023 — Income from Non-Controlling Interests soared 242.08% — and 2025, when it sank 250.0%.
- Oramed Pharmaceuticals' Income from Non-Controlling Interests stood at -$751000.0 in 2021, then advanced by 21.84% to -$587000.0 in 2022, then surged by 242.08% to $834000.0 in 2023, then slumped by 101.2% to -$10000.0 in 2024, then soared by 40.0% to -$6000.0 in 2025.
- Business Quant data shows ORMP's Income from Non-Controlling Interests at -$6000.0 in Q3 2025, -$28000.0 in Q2 2025, and -$10000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Oramed Pharmaceuticals | 170.25 Mn | 170.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -6,000.00 |
| Jun 30, 2025 | -28,000.00 |
| Dec 31, 2024 | -10,000.00 |
| Sep 30, 2024 | -23,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | -2,000.00 |
| Dec 31, 2023 | 834,000.00 |
| Sep 30, 2023 | -62,000.00 |
| Jun 30, 2023 | -119,000.00 |
| Mar 31, 2023 | -216,000.00 |
| Dec 31, 2022 | -587,000.00 |
| Sep 30, 2022 | -193,000.00 |
| Jun 30, 2022 | -534,000.00 |
| Mar 31, 2022 | -283,000.00 |
| Aug 31, 2021 | -751,000.00 |
| Aug 31, 2018 | 504,000.00 |
| May 31, 2018 | -115,000.00 |
| Feb 28, 2018 | -414,000.00 |
| Nov 30, 2017 | 326,000.00 |
| Aug 31, 2017 | -96,000.00 |